![Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/836ddd64-746c-42be-a466-bc87d43afc1a/gr1.gif)
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
![Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study - The Lancet Global Health Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study - The Lancet Global Health](https://www.thelancet.com/cms/asset/86358def-b40c-463b-b299-64f05ea2b6c3/gr1.gif)
Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study - The Lancet Global Health
Solved: How to stop "data set limit reached" from appearing in my process flow... - SAS Support Communities
Solved: How to stop "data set limit reached" from appearing in my process flow... - SAS Support Communities
Natural Organic Matter, Orthophosphate, pH, and Growth Phase Can Limit Copper Antimicrobial Efficacy for Legionella in Drinking Water | Environmental Science & Technology
![Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2–3 trial - The Lancet Global Health Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2–3 trial - The Lancet Global Health](https://www.thelancet.com/cms/asset/4d18a365-6c6c-493b-b3b6-6f8e6cebd5aa/gr1.jpg)
Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2–3 trial - The Lancet Global Health
![How to fix “Exceeded the Maximum Number of Computer Accounts Allowed to Create in this Domain” | just another windows noob ? How to fix “Exceeded the Maximum Number of Computer Accounts Allowed to Create in this Domain” | just another windows noob ?](https://www.niallbrady.com/wp-content/uploads/2019/02/exceeded.png)
How to fix “Exceeded the Maximum Number of Computer Accounts Allowed to Create in this Domain” | just another windows noob ?
![49195 - In SAS® Enterprise Guide®, you might receive an error that the data set limit has been reached 49195 - In SAS® Enterprise Guide®, you might receive an error that the data set limit has been reached](http://support.sas.com/kb/49/addl/fusion_49195_2_datasetoption.jpg)
49195 - In SAS® Enterprise Guide®, you might receive an error that the data set limit has been reached
![ESSD - HydroGFD3.0 (Hydrological Global Forcing Data): a 25 km global precipitation and temperature data set updated in near-real time ESSD - HydroGFD3.0 (Hydrological Global Forcing Data): a 25 km global precipitation and temperature data set updated in near-real time](https://essd.copernicus.org/articles/13/1531/2021/essd-13-1531-2021-avatar-web.png)
ESSD - HydroGFD3.0 (Hydrological Global Forcing Data): a 25 km global precipitation and temperature data set updated in near-real time
![A randomized clinical trial of lipid metabolism modulation with fenofibrate for acute coronavirus disease 2019 | Nature Metabolism A randomized clinical trial of lipid metabolism modulation with fenofibrate for acute coronavirus disease 2019 | Nature Metabolism](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs42255-022-00698-3/MediaObjects/42255_2022_698_Fig1_HTML.png)